TY - JOUR T1 - Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant JF - bioRxiv DO - 10.1101/2021.01.24.427991 SP - 2021.01.24.427991 AU - Ann-Kathrin Reuschl AU - Lucy G. Thorne AU - Lorena Zuliani-Alvarez AU - Mehdi Bouhaddou AU - Kirsten Obernier AU - Margaret Soucheray AU - Jane Turner AU - Jacqueline M. Fabius AU - Gina T. Nguyen AU - Danielle L. Swaney AU - Romel Rosales AU - Kris M. White AU - Pablo Avilés AU - Ilsa T. Kirby AU - James E. Melnyk AU - Ying Shi AU - Ziyang Zhang AU - Kevan M. Shokat AU - Adolfo García-Sastre AU - Clare Jolly AU - Gregory J. Towers AU - Nevan J. Krogan Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/01/24/2021.01.24.427991.abstract N2 - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide and massive societal and economic burden. Recently, a new variant of SARS-CoV-2, known as B.1.1.7, was first detected in the United Kingdom and is spreading in several other countries, heightening public health concern and raising questions as to the resulting effectiveness of vaccines and therapeutic interventions. We and others previously identified host-directed therapies with antiviral efficacy against SARS-CoV-2 infection. Less prone to the development of therapy resistance, host-directed drugs represent promising therapeutic options to combat emerging viral variants as host genes possess a lower propensity to mutate compared to viral genes. Here, in the first study of the full-length B.1.1.7 variant virus, we find two host-directed drugs, plitidepsin (aplidin; inhibits translation elongation factor eEF1A) and ralimetinib (inhibits p38 MAP kinase cascade), as well as remdesivir, to possess similar antiviral activity against both the early-lineage SARS-CoV-2 and the B.1.1.7 variant, evaluated in both human gastrointestinal and lung epithelial cell lines. We find that plitidepsin is over an order of magnitude more potent than remdesivir against both viruses. These results highlight the importance of continued development of host-directed therapeutics to combat current and future coronavirus variant outbreaks.Competing Interest StatementThe Garcia-Sastre Laboratory has received research support from Pfizer, Senhwa Biosciences and 7Hills Pharma. Adolfo Garcia-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. The Krogan Laboratory receives funding from Roche and VIR and Nevan Krogan has consulting agreements with Maze Therapeutics and Interline Therapeutics. Kevan Shokat has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Revolution Medicines, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Turning Point Therapeutics, Ikena, Nextech. Pablo Aviles is an employee and shareholder of PharmaMar, SA (Madrid, Spain). ER -